NCT04337138

A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World

Characteristics, Treatment Patterns, and Clinical Outcomes in Acute Myeloid Leukemia (AML) Patients Using Mylotarg - a US Real-World Study Using Electronic Medical Record Data

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 32 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this observational study is to describe treatment patterns and effectiveness outcomes in a sample of oncology patients treated for AML with Mylotarg through up to two additional relapsed/refractory (R/R)-based lines of therapy (through third-line therapy). The study will use United States oncology electronic medical record (EMR) data. All study data are secondary data and will have been collected retrospectively from existing clinical data originally collected as part of routine care.

Conditions

• Leukemia, Myeloid, Acute

Interventions

Type	Name	Description
DRUG	Gemtuzumab Ozogamicin	Gemtuzumab Ozogamicin (Mylotarg) administered in any form or combination

Timeline

• Start date: 2020-04-07
• Primary completion: 2020-07-31
• Completion: 2020-07-31
• First posted: 2020-04-07
• Last updated: 2021-08-09
• Results posted: 2021-08-09

Locations

1 site across 1 country: United States